A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy
Details
Age
Adult
Type of Study
Treatment
Locations
Brain Imaging Center (BIC)
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Thomas Ragole, MD
Study ID
Protocol Number: 22-1143
More information available at ClinicalTrials.gov: NCT05397470
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers